Protea Inks Cancer Analysis Alliance with MSKCC, Dana-Farber | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences Group said today that it has undertaken a collaborative research effort with Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute with an initial focus on lung cancer.

The partners will use Protea's next generation LAESI (Laser Ablation Electrospray Ionization) direct molecular imaging technology to analyze cancer cells. Protea said they will "generate molecular data profiles of cancer cells in tissue and biofluids to improve the understanding of a cancer's origin."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.